REFERENCES
- Elliott AM, Smith BH, Lancet. 1999;354:1248–1252.
- Pickering G, Jourdan D, Eur J Pain. 2006;10:379–384.
- Dillon CF, Rasch EK, J Rheumatol. 2006;33:2271–2279.
- Austrian JS, Kerns RD J Am Geriatr Soc. 2005; 53:856–861.
- American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. J Am Geriatr Soc. 2009;57:1331–1346.
- NICE. Osteoarthritis. The care and management of adults with osteoarthritis. CG59. London: NICE; 2008. Available at: www.nice.org.uk. Accessed February 1, 2013.
- Zhang W, Moskowitz RW, Osteoarthritis Cartilage. 2008; 16:137–162.
- Simon LS, Grierson LM, Pain. 2009;143:238–245.
- The British Pain Society. Opioids for persistent pain: good practice. London: The British Pain Society; 2010. Available at: www.britishpainsociety.org/book_opioid_main.pdf. Accessed February 1, 2013.
- Lee CR, McTavish D, Drugs. 1993;46:313–240.
- Barber JB, Gibson SJ. Drug Saf. 2009;32:457–474.
- Codeine phosphate tablets 15 mg SPC. 2011. Available at: www.medicines.org. Accessed February 13, 2013.
- Pergolizzi J, Böger RH, Pain Pract. 2008;8:287–313.
- Ackerman SJ, Knight T, Consult Pharm. 2004;19:118–132.
- Al-Tawil N, Odar-Cederlöf I, Eur J Clin Pharmacol. 2013;69:143–149.
- Transtec 35, 52.5 and 70 microgram transdermal patch SPC. 2010. Available at: www.medicines.org. Accessed February 13, 2013.
- Kress HG. Eur J Pain. 2009;13:219–230.
- BuTrans 5, 10 and 20 microgram transdermal patch SPC. 2010. Available at: www.medicines.org. AccessedFebruary 26, 2013).
- Likar R, Vadlau EM, Clin J Pain. 2008;24:536–543.
- Breivik H, Ljossa TM, Scand J Pain. 2010;1:122–141.